adenine has been researched along with Pneumonia, Pneumocystis in 4 studies
Pneumonia, Pneumocystis: A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lee, R | 1 |
Nayernama, A | 1 |
Jones, SC | 1 |
Wroblewski, T | 1 |
Waldron, PE | 1 |
Cheng, MP | 1 |
Kusztos, AE | 1 |
Gustine, JN | 1 |
Dryden-Peterson, SL | 1 |
Dubeau, TE | 1 |
Woolley, AE | 1 |
Hammond, SP | 1 |
Baden, LR | 1 |
Treon, SP | 1 |
Castillo, JJ | 1 |
Issa, NC | 1 |
Ahn, IE | 1 |
Jerussi, T | 1 |
Farooqui, M | 1 |
Tian, X | 1 |
Wiestner, A | 1 |
Gea-Banacloche, J | 1 |
Romero, E | 1 |
Hernández, JM | 1 |
Jarilla, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)[NCT02514083] | Phase 2 | 29 participants (Actual) | Interventional | 2015-12-09 | Active, not recruiting | ||
A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733] | Phase 2 | 86 participants (Actual) | Interventional | 2012-01-05 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
Elderly Cohort | 93.9 |
TP53 Cohort | 95.8 |
1 trial available for adenine and Pneumonia, Pneumocystis
Article | Year |
---|---|
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
3 other studies available for adenine and Pneumonia, Pneumocystis
Article | Year |
---|---|
Ibrutinib-associated Pneumocystis jirovecii pneumonia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Piperidines; Pneumocysti | 2017 |
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Invasive Fungal Infe | 2019 |
[Renal tuberculosis and human immunodeficiency virus infection].
Topics: Acute Kidney Injury; Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral | 2009 |